言語を選択

PSGL-1

PSGL-1 詳細

英語名	P-selectin glycoprotein ligand-1	市販薬剤の数	0
治験薬の数	4	ターゲットの別称	P-selectin glycoprotein ligand 1，PSGL-1，SELPLG，Selectin P Ligand，Cutaneous Lymphocyte-Associated Associated Antigen，CD162 Antigen，CD162，PSGL1，CLA
研究＆開発段階	Phase 2 Clinical

英語名	P-selectin glycoprotein ligand-1
ターゲットの別称	P-selectin glycoprotein ligand 1，PSGL-1，SELPLG，Selectin P Ligand，Cutaneous Lymphocyte-Associated Associated Antigen，CD162 Antigen，CD162，PSGL1，CLA
市販薬剤の数	0
治験薬の数	4
研究＆開発段階	Phase 2 Clinical

PSGL-1 製品リスト

属性
Protein (2)
製品ライブラリ
オンライン (2)
種
Human (2)
タグ
His Tag (1)His Tag & Avi Tag (1)
マーカー
Unconjugated (1)Biotin-labeled (1)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
PS1-H52H9	Human	HEK293	Human PSGL-1 / CD162 Protein, His Tag
PS1-H82E4	Human	HEK293	Biotinylated Human PSGL-1 / CD162 Protein, His,Avitag™

総数量2

PSGL-1バックグランド

P-selectin glycoprotein ligand 1 (PSGL-1) is also known as Selectin P ligand (SELPLG), CD antigen CD162. PSGL-1 is disulfide-linked homodimer which is the high affinitycounter-receptor for P-selectin on expressed on activated endothelial cells and platelets. PSGL-1 / SELPLG interacts with P-, E- and L-selectins, through their lectin/EGF domains, is required for promoting recruitment and rolling of leukocytes. These interactions require sialyl Lewis X glycan modification but there is a differing dependence for tyrosine sulfations. Dimerization appears not to be required for P-selectin/SELP binding. PSGL-1 can interact with SNX20, MSN and SYK. PSGL-1 / SELPLG mediate the activation of SYK by SELPLG.

PSGL-1分子の別称

PSGL1,CD162,SELPLG,Selectin P ligand

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Cepeprubart	SelK-2	Phase 2 Clinical	Selexys	Asthma; Pulmonary Disease, Chronic Obstructive; Venous Thromboembolism	詳細
Leiolizumab	AbGn 168H2; AbGn-268; AbGn-168H2; ALTB-268	Phase 2 Clinical	Altrubio Inc	Arthritis, Psoriatic; Colitis, Ulcerative	詳細
Neihulizumab	AbGn-168; AbGn-168H; ALTB-168	Phase 1 Clinical	Altrubio Inc	Arthritis, Psoriatic; Colitis, Ulcerative; Graft vs Host Disease; Plaque psoriasis; Psoriasis	詳細
SSGJ-617	SSGJ-617; SSGJ617; 61X; VTX-0811; 617	Phase 1 Clinical	Verseau Therapeutics Inc	Solid tumours	詳細